3 New Strong Buy Ratings from Top-Rated Analysts: 04/15/2025

Our Strong Buy Stocks from Top Wall Street Analysts screener is a gateway to high-quality stock picks from the best-performing analysts. It’s a premium feature on our site, but we’ve unlocked a FREE sampling below: 

• Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) continues its steady rise 
• This company loves stock volatility: BGC Group Inc. (NASDAQ: BGC)
• Why Nutex Health Inc. (NASDAQ: NUTX) surged 300% in 3 months

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

1. Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

A biotech leader with a strong position in cystic fibrosis treatments, Vertex Pharmaceuticals has recently expanded into pain management, sickle cell disease, and type 1 diabetes treatments. The company is rapidly approaching profitability, VRTX stock has been on a steady rise since the year began, and there’s quite a strong balance sheet in there as well, which can easily be leveraged to finance further growth.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $484.22 — get current quote > 

Max 1-year forecast: $586.00 

Why we’re watching:

• Vertex Pharmaceuticals has attracted a lot of attention — 18 analysts currently cover it. At present, the stock has 8 Strong Buy ratings, 3 Buy ratings, and 7 Hold ratings. See the ratings
• Bank of America’s Ying Huang (a top 18% rated analyst) recently reissued a Strong Buy rating, with a price target that was hiked from $555 to $567.
• Huang attributed their price target hike to results from a survey of 35 key opinion leaders who treat 6,200 acute pain patients each month regarding their expectations for Journavx usage.
• Based on the data, the BofA analyst told investors to expect $100M in revenue from Vertex Pharmaceuticals in FY 2025, up from their prior estimate of $42M previously, and peak U.S. sales of $1.5B in 2032, up from their prior $1.2B in 2033.
• VRTX stock carries a Zen Rating of B. Per a holistic analysis of 115 factors that correlate with outsized gains, it ranks in the top 9% of stocks on the whole.
• Safety and Financials are Vertex Pharmaceuticals’ greatest strengths — it ranks in the top 19% in both categories. (See all 7 Zen Component Grades here >)

2. BGC Group Inc. (NASDAQ: BGC)

This business clears trades across the bond, forex, and equities markets. Fun fact — Commerce Secretary Howard Lutnick used to be its CEO. BGC Group is at the heart of institutional trading infrastructure, which gives it a strong degree of immunity to macro disruptions. As long as trades are being made, BGC Group profits.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $8.32 — get current quote > 

Max 1-year forecast: $15.00 

Why we’re watching:

• At present, 2 analysts cover BGC stock — and both issue Strong Buy ratings. See the ratings
• Moreover, with one price target at $14 and the other at $15, the implied upside from analysts equates to 68.27% and 80.29%.
• Patrick Moley of Piper Sandler (a top 5% rated analyst) set the $14 price target on April 8, increasing his forecast from $12.
• In a sector preview note, the analyst predicted that "strong results and a favorable macro setup should drive continued outperformance for exchange and trading company stocks."
• BGC stock is the top-rated stock in the Capital Market industry.
• BGC Group stock has a Zen Rating of A, and ranks in the 97th percentile of the more than 4,600 stocks that we track.
• In terms of its Value rating,  BGC stock ranks in the top 14%. However, it ranks even more highly in terms of Financials, where it ranks in the 92nd percentile
• With that being said, Artificial Intelligence is BGC’s strongest Component Grade rating. A neural network trained on more than 20 years of fundamental and technical data has picked up on plenty of subtle signs that hint at capital appreciation to come. In terms of its AI rating, the stock is in the top 3%. (See all 7 Zen Component Grades here >)

3. Nutex Health Inc. (NASDAQ: NUTX)

We’re kicking this week off with something a little different compared to our standard fare. Nutex Health stock has surged by 84.99% in a week, 187.96% in a month, and 329.23% in the past three months. At present, it has just two analysts covering it. However, this isn’t a late April Fool's joke — there’s obviously something at play here, and we believe it deserves attention.

Zen Rating: A (Strong Buy)  — see full analysis >  

Recent Price: $132.03  — get current quote > 

Max 1-year forecast: $150.00 

Why we’re watching:

• Since we used the intro to give you a slightly bigger-picture view, let’s backtrack here. Nutex Health operates small-scale health facilities, micro-hospitals, and speciality hospitals, as well as a cloud-based platform that aggregates clinical and claims data.
• Under the No Surpises Act, the company has started to submit as much as 70% of its billable visits to arbitration — allowing it to counteract insurer underpayment. Their success rate under arbitration currently stands at roughly 80%.
• For the company’s latest quarterly report, analysts were expecting to see a $0.12 loss per share — instead, Nutex posted a gain of $11.12 per share.  In addition, revenues more than tripled on a year-over-year (YoY) basis.
• Benchmark’s Bill Sutherland (a top 26% rated analyst) maintained a Strong Buy rating on Nutex Health stock, and increased his price target from $45 to $60 in the aftermath. Now, he has once again increased his price target — this time to $150. 
• Sutherland called the quarter "another big beat from top to bottom," highlighted by revenue and Adjusted EBITDA growth of 26% and 974%, respectively.
• The analyst explained that Nutex Health's "initiatives to increase patient volumes for higher-value services continued to drive growth and margin expansion."
• NUTX has a Zen Rating of A. Stocks of this caliber have provided an average annual return of 32.52% since the turn of the millennium. At present, Nutex Health stock ranks in the top 2% of equities per our proprietary quant rating system.
• Nutex Health is also the top-rated stock in the Health Information Service industry.
• In terms of Component Grade ratings, NUTX shares rank highly in terms of Sentiment, Growth, and Momentum — in the top 2%, 3%, and 5%, respectively. (See all 7 Zen Component Grades here >)
• P.S. — this is a highly unusual one, so we’d recommend quite a bit of caution. There’s no telling whether or not the arbitration strategy is sustainable. With that being said, it was put into place in July of 2024 — but even though it seems to be working at the moment, there’s plenty of policy risk here.

What to Do Next?

• 8 Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return > 
• 4 Step Process to Find More 100%+ Stock Winners >

Want to get in touch? Email us at news@wallstreetzen.com.